XML 20 R11.htm IDEA: XBRL DOCUMENT
v3.26.1

Net Loss Per Share | 6 Months Ended
--- | ---
Jun. 30, 2026
Earnings Per Share [Abstract] |
Net Loss Per Share | Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share for the three and six months ended June 30, 2026, and 2025 (in thousands, except number of shares):
| Three months ended June 30, |  | Six months ended June 30,
| 2026 |  | 2025 |  | 2026 |  | 2025
Numerator: |  |  |  |  |  |  |
Net loss | $ | (10,599) |  |  | $ | (21,126) |  |  | $ | (16,133) |  |  | $ | (40,784) |
Net loss attributable to noncontrolling interest | 19 |  |  | 2 |  |  | 22 |  |  | 12 |
Net loss attributable to Barinthus Biotherapeutics plc shareholders | $ | (10,580) |  |  | $ | (21,124) |  |  | $ | (16,111) |  |  | $ | (40,772) |
Denominator: |  |  |  |  |  |  |
Weighted-average ordinary shares outstanding, basic | 40,848,893 |  | 40,343,521 |  | 40,848,893 |  | 40,304,584
Weighted-average ordinary shares outstanding, diluted | 40,848,893 |  | 40,343,521 |  | 40,848,893 |  | 40,304,584
Net loss per share attributable to ordinary shareholders, basic | $ | (0.26) |  |  | $ | (0.52) |  |  | $ | (0.39) |  |  | $ | (1.01) |
Net loss per share attributable to ordinary shareholders, diluted | $ | (0.26) |  |  | $ | (0.52) |  |  | $ | (0.39) |  |  | $ | (1.01) |
Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share, as the inclusion of all potential ordinary share equivalents outstanding would have been anti-dilutive. As of June 30, 2026, 3,992,720 potential ordinary shares issuable for stock options were excluded from the computation of diluted weighted-average shares outstanding because including these shares would have had an anti-dilutive effect (June 30, 2025: 7,625,728).

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-12 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 20 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481468/505-20-05-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration